TG Therapeutics Expects Prelim. Q4 US Net Product Revenue For Briumvi At $103.6 Mln

(RTTNews) - TG Therapeutics, Inc. (TGTX), Tuesday announced preliminary fourth-quarter and full year 2024 results of Briumvi, a novel monoclonal antibody used for the treatment of relapsing forms of multiple sclerosis in adults.

The company expects Briumvi U.S. net product revenue of $103.6 million for the fourth quarter, and $310 million for the full year 2024.

Looking forward, TG anticipates total global revenue of approximately $540 million for the fiscal year 2025, including Briumvi U.S. net product revenue of approximately $525 million.

In the pre-market hours, TG's stock is moving up 5.38 percent, to $29.16 on the Nasdaq.